Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Cannady

Otolaryngology Philadelphia, PA Medical Doctor

NPI 1033394242 CMS profile 137467

800 Spruce St, Philadelphia, PA 19107

Open in the dashboard

General payments

$33,116

38 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$18,624 paid to institutions, not to them · program year 2019

Through program year 2025, Steven Cannady of Philadelphia, PA is reported in the CMS Open Payments database as having received $33,116 across 38 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $18,624 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Otolaryngology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $12,434 2
2023 General $221 2
2022 General $28 1
2021 General $10,577 15
2019 General $9,857 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Cannady
  • Otolaryngology median
  • Middle half of Otolaryngology
  • National median

In program year 2025, general payments to Steven Cannady were reported at $12,434. Among 6,588 Otolaryngology profiles paid that year, the median was $317 and the middle half received between $125 and $815.

Show as a table
Year Steven Cannady Otolaryngology median Middle half National median
2019 $9,857 $194 $82–$512 $163
2020 $0 $118 $42–$280 $114
2021 $10,577 $167 $63–$444 $132
2022 $28 $216 $84–$545 $149
2023 $221 $235 $93–$588 $160
2024 $0 $280 $111–$699 $164
2025 $12,434 $317 $125–$815 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Janssen Research & Development, LLC $10,769 1 payment
  2. Medical Device Business Services, Inc. $10,436 13 payments
  3. Zimmer Biomet Holdings, Inc. $9,819 16 payments
  4. Janssen Scientific Affairs, LLC $1,665 1 payment
  5. Baxter Healthcare $136 1 payment
  6. AxoGen $89 1 payment
  7. Atos Medical Inc $85 1 payment
  8. Intuitive Surgical, Inc. $52 1 payment
  9. DePuy Synthes Sales Inc. $37 2 payments
  10. Acera Surgical, Inc. $28 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $29,405 7 payments
  2. Travel and Lodging $2,728 12 payments
  3. Food and Beverage $983 19 payments
Products named General payments · program years 2019–2025
  1. CMF & Thoracic Product Portfolio $9,688 14 payments
  2. MATRIXMANDIBLE CMF-Trauma $9,363 2 payments
  3. MATRIXMIDFACE $9,363 2 payments
  4. Traumaone $132 2 payments
  5. TRUMATCH $119 1 payment
  6. Avance Nerve Graft $89 1 payment
  7. Provox Life Home HME $85 1 payment
  8. Da Vinci Surgical System $52 1 payment
  9. MATRIXMANDIBLE CMF-Trauma $37 2 payments
  10. Restrata Wound Matrix $28 1 payment
  11. Other $34 2 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

11

Median for Otolaryngology: 297

Drug cost

$49

Median for Otolaryngology: $6,314

Branded share of claims

0%

Median for Otolaryngology: 10.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gabapentin Generic 11 $49

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 9,296 Part D prescribers listed as Otolaryngology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 63 billing codes

Paid by Medicare

$116,464

Medicare's payments for the services billed

Medicare patients

189

Average age 73

Services billed

483

77 women, 112 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 71%
Arthritis 35%
Ischemic heart disease 34%
Diabetes 29%
Atrial fibrillation 22%
Chronic kidney disease 22%
Depression 22%
COPD 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

38 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Otolaryngology in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record